MedicalCV AtriLaze 1064nm laser:
This article was originally published in Clinica
Executive Summary
The US FDA has given MedicalCV 510(k) market clearance to expand the functionality of its AtriLaze surgical ablation system for treating atrial fibrillation (AF), by allowing the device to deliver 1064nm wavelength laser energy. The system is already cleared for the delivery of 810nm laser light. The new wavelength optimises the application of laser energy to cardiac tissue and is particularly suitable for the miniaturisation required to use laser technology through smaller access ports said MedicalCV. This brings the firm a significant step closer to delivering a "truly stand-alone, minimally invasive" AF therapy procedure, the Inver Grove Heights, Minnesota company added.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.